ATE445407T1 - Methoden und kompositionen um diabetes zu behandeln - Google Patents

Methoden und kompositionen um diabetes zu behandeln

Info

Publication number: ATE445407T1
Authority: AT; Austria
Prior art keywords: compositions; methods; treat diabetes; gastrin; immunosuppressant
Prior art date: 2002-06-07

Application number

AT07010865T

Other languages

English (en)

Inventor

Stephen Brand

Antonio Cruz

Original Assignee

Waratah Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-07

Filing date

2003-06-09

Publication date

2009-10-15

2003-06-09 Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE445407T1 publication Critical patent/ATE445407T1/de

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 2
108010089448 Cholecystokinin B Receptor Proteins 0.000 abstract 1
102000004859 Cholecystokinin Receptors Human genes 0.000 abstract 1
108090001085 Cholecystokinin Receptors Proteins 0.000 abstract 1
102100021022 Gastrin Human genes 0.000 abstract 1
102000052874 Gastrin receptors Human genes 0.000 abstract 1
108010052343 Gastrins Proteins 0.000 abstract 1
230000008629 immune suppression Effects 0.000 abstract 1
229960003444 immunosuppressant agent Drugs 0.000 abstract 1
230000001861 immunosuppressant effect Effects 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000009707 neogenesis Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Transplantation (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT07010865T 2002-06-07 2003-06-09 Methoden und kompositionen um diabetes zu behandeln ATE445407T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38703202P	2002-06-07	2002-06-07
US43059002P	2002-12-03	2002-12-03

Publications (1)

Publication Number	Publication Date
ATE445407T1 true ATE445407T1 (de)	2009-10-15

Family

ID=29739925

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT03757483T ATE375166T1 (de)	2002-06-07	2003-06-09	Zusammensetzungen und verfahren zur behandlung von diabetes
AT07010865T ATE445407T1 (de)	2002-06-07	2003-06-09	Methoden und kompositionen um diabetes zu behandeln

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT03757483T ATE375166T1 (de)	2002-06-07	2003-06-09	Zusammensetzungen und verfahren zur behandlung von diabetes

Country Status (12)

Country	Link
US (3)	US7560425B2 (de)
EP (1)	EP1511509B1 (de)
JP (1)	JP2005533775A (de)
KR (1)	KR20050048542A (de)
CN (1)	CN1671407B (de)
AT (2)	ATE375166T1 (de)
AU (1)	AU2003243501A1 (de)
CA (1)	CA2486584A1 (de)
DE (2)	DE60329724D1 (de)
ES (1)	ES2334268T3 (de)
IL (2)	IL165285A0 (de)
WO (1)	WO2003103701A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
IL156828A0 (en)	2001-01-12	2004-02-08	Waratah Pharmaceuticals Inc	Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
US7037504B2 (en) *	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
IL165242A0 (en) *	2002-05-24	2005-12-18	Waratah Pharmaceuticals Inc	Treatment for diabetes
DE60329724D1 (de)	2002-06-07	2009-11-26	Waratah Pharmaceuticals Inc	Methoden und Kompositionen um Diabetes zu behandeln
EP1837031B1 (de) *	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methoden und Kompositionen um Diabetes zu behandeln
US20040229810A1 (en) *	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
BRPI0409632A (pt) *	2003-04-22	2006-04-25	Wyeth Corp	combinações antineoplásticas
US20080039379A1 (en) *	2003-05-27	2008-02-14	Waratah Pharmaceuticals, Inc.	Compositions Comprising Gastrin Compounds and Their Use in Diabetes
JP2007519642A (ja) *	2004-01-30	2007-07-19	ワラタファーマシューティカルズ，インコーポレイテッド	血糖値を調節するためのｇｌｐ−１アゴニストとガストリンとの合わせた使用
WO2006002532A1 (en) *	2004-07-01	2006-01-12	Waratah Pharmaceuticals, Inc.	Methods and compositions using cd3 agonists
US20140162965A1 (en)	2004-08-25	2014-06-12	Aegis Therapeutics, Inc.	Compositions for oral drug administration
US20060046962A1 (en)	2004-08-25	2006-03-02	Aegis Therapeutics Llc	Absorption enhancers for drug administration
US8268791B2 (en) *	2004-08-25	2012-09-18	Aegis Therapeutics, Llc.	Alkylglycoside compositions for drug administration
US9895444B2 (en)	2004-08-25	2018-02-20	Aegis Therapeutics, Llc	Compositions for drug administration
US20080268093A1 (en) *	2004-12-30	2008-10-30	Eric Vaun Bowman	Compositions For Feline Consumption
US20100144613A1 (en) *	2005-10-07	2010-06-10	Antonio Cruz	Combined use of DPP-IV Inhibitors and Gastrin Compounds
US11311477B2 (en) *	2006-03-07	2022-04-26	Sgn Nanopharma Inc.	Ophthalmic preparations
US10137083B2 (en) *	2006-03-07	2018-11-27	SGN Nanopharma Inc	Ophthalmic preparations
US8173594B2 (en) *	2006-06-23	2012-05-08	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) *	2006-06-23	2008-09-16	Aegis Therapeutics, Inc.	Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) *	2006-06-23	2009-12-31	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) *	2006-06-23	2011-12-27	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) *	2006-06-23	2011-08-16	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en)	2006-06-23	2012-07-24	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
US20090312250A1 (en) *	2006-07-14	2009-12-17	Postech Academy-Industry Foundation	Epidermal growth factor increasing insulin secretion and lowering blood glucose
EP2271347B1 (de)	2008-03-28	2016-05-11	Hale Biopharma Ventures, Llc	Verabreichung von benzodiazepin-zusammensetzungen
EP2318012A4 (de) *	2008-07-25	2011-08-24	Univ Johns Hopkins	Verfahren und zusammensetzungen zur behandlung und prävention von automimmunerkrankungen
US8440631B2 (en)	2008-12-22	2013-05-14	Aegis Therapeutics, Llc	Compositions for drug administration
US8940705B2 (en)	2009-01-09	2015-01-27	The Regents Of The University Of California	Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone
PT3415139T (pt)	2011-06-14	2022-06-20	Neurelis Inc	Administração de benzodiazepina
HK1198467A1 (en) *	2011-08-03	2015-05-08	Zhongmin MA	Treatment of type 2 diabetes with fty720
MX2014005358A (es)	2011-11-03	2014-09-12	Tolera Therapeutics Inc	Anticuerpo y metodos para la inhibicion selectiva de respuestas mediadas por celulas t.
US20130273089A1 (en)	2011-11-03	2013-10-17	Tolera Therapeutics, Inc.	Antibody and methods for selective inhibition of t-cell responses
WO2014138003A1 (en) *	2013-03-04	2014-09-12	Neuralstem, Inc.	Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders
US11116777B2 (en)	2015-11-10	2021-09-14	City Of Hope	Conditioning regimens and methods for inducing mixed chimerism
WO2017116569A1 (en) *	2015-12-31	2017-07-06	City Of Hope	Methods for treating diabetes
US20210355448A1 (en) *	2017-06-26	2021-11-18	City Of Hope	Methods of islet cell culture
CA3106651A1 (en) *	2018-07-18	2020-01-23	Stephen YOO	Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idus)
BR112021022682A2 (pt)	2019-05-14	2022-02-22	Provention Bio Inc	Métodos e composições para prevenir diabetes do tipo 1
BR112022025381A2 (pt)	2020-06-11	2023-01-24	Provention Bio Inc	Métodos e composições para prevenir diabetes tipo 1
CA3241242A1 (en) *	2021-06-10	2022-12-15	Fouad Kandeel	Compositions and methods for islet cell transplants

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL101353A0 (en)	1991-04-03	1992-11-15	American Home Prod	Pharmaceutical compositions for treating diabetes
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
US6558952B1 (en)	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
US5885956A (en)	1992-12-14	1999-03-23	Research Triangle Pharmaceuticals	Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
EP0752882B1 (de) *	1994-01-24	2002-08-21	Waratah Pharmaceuticals Inc.	Behandlung von diabetes
US5624895A (en) *	1994-02-18	1997-04-29	Georgetown University Medical Center	Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US20040037818A1 (en)	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
DE69911975T2 (de)	1998-07-31	2004-09-09	Novo Nordisk A/S	In-vitro stimulation von beta zellen vermehrung
US6610535B1 (en)	2000-02-10	2003-08-26	Es Cell International Pte Ltd.	Progenitor cells and methods and uses related thereto
JP2003528135A (ja)	2000-03-31	2003-09-24	プロバイオドラッグアーゲー	糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
IL156828A0 (en)	2001-01-12	2004-02-08	Waratah Pharmaceuticals Inc	Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
DE60224284T2 (de)	2001-06-28	2008-12-18	Novo Nordisk A/S	Stabile formulierung von modifiziertem glp-1
US7037504B2 (en)	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
IL165242A0 (en)	2002-05-24	2005-12-18	Waratah Pharmaceuticals Inc	Treatment for diabetes
EP1837031B1 (de)	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methoden und Kompositionen um Diabetes zu behandeln
DE60329724D1 (de)	2002-06-07	2009-11-26	Waratah Pharmaceuticals Inc	Methoden und Kompositionen um Diabetes zu behandeln
US20040229810A1 (en)	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
KR20050074492A (ko)	2002-10-22	2005-07-18	와라타 파마수티컬즈, 인크.	당뇨병의 치료
CA2522895A1 (en)	2003-04-30	2004-11-11	Waratah Pharmaceuticals, Inc.	Combined use of keratinocyte growth factor agonists and gastrin compounds
JP2007513059A (ja)	2003-05-27	2007-05-24	ワラタファーマシューティカルズ，インコーポレイテッド	ガストリン化合物を含む組成物および糖尿病におけるそれらの使用
JP2007519642A (ja)	2004-01-30	2007-07-19	ワラタファーマシューティカルズ，インコーポレイテッド	血糖値を調節するためのｇｌｐ−１アゴニストとガストリンとの合わせた使用
WO2006002532A1 (en)	2004-07-01	2006-01-12	Waratah Pharmaceuticals, Inc.	Methods and compositions using cd3 agonists
US20100144613A1 (en)	2005-10-07	2010-06-10	Antonio Cruz	Combined use of DPP-IV Inhibitors and Gastrin Compounds
WO2007062531A1 (en)	2005-12-02	2007-06-07	Waratah Pharmaceuticals, Inc.	Combination treatments with gastrin agonists for diabetes and related diseases
WO2007095737A1 (en)	2006-02-21	2007-08-30	Waratah Pharmaceuticals Inc.	Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound

2003
- 2003-06-09 DE DE60329724T patent/DE60329724D1/de not_active Expired - Lifetime
- 2003-06-09 US US10/517,135 patent/US7560425B2/en not_active Expired - Fee Related
- 2003-06-09 WO PCT/US2003/018377 patent/WO2003103701A1/en active IP Right Grant
- 2003-06-09 AT AT03757483T patent/ATE375166T1/de not_active IP Right Cessation
- 2003-06-09 AT AT07010865T patent/ATE445407T1/de not_active IP Right Cessation
- 2003-06-09 CA CA002486584A patent/CA2486584A1/en not_active Abandoned
- 2003-06-09 IL IL16528503A patent/IL165285A0/xx unknown
- 2003-06-09 JP JP2004510820A patent/JP2005533775A/ja active Pending
- 2003-06-09 KR KR1020047019788A patent/KR20050048542A/ko not_active Ceased
- 2003-06-09 US US10/457,126 patent/US20040023885A1/en not_active Abandoned
- 2003-06-09 EP EP03757483A patent/EP1511509B1/de not_active Expired - Lifetime
- 2003-06-09 DE DE60316798T patent/DE60316798T2/de not_active Expired - Lifetime
- 2003-06-09 AU AU2003243501A patent/AU2003243501A1/en not_active Abandoned
- 2003-06-09 CN CN038185261A patent/CN1671407B/zh not_active Expired - Fee Related
- 2003-06-09 ES ES07010865T patent/ES2334268T3/es not_active Expired - Lifetime
2004
- 2004-11-18 IL IL165285A patent/IL165285A/en not_active IP Right Cessation
2009
- 2009-04-08 US US12/420,212 patent/US20090269337A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1511509A1 (de)	2005-03-09
US7560425B2 (en)	2009-07-14
WO2003103701A1 (en)	2003-12-18
DE60316798T2 (de)	2008-07-24
ATE375166T1 (de)	2007-10-15
DE60316798D1 (de)	2007-11-22
EP1511509A4 (de)	2005-04-27
US20060183674A1 (en)	2006-08-17
CA2486584A1 (en)	2003-12-18
ES2334268T3 (es)	2010-03-08
IL165285A0 (en)	2005-12-18
CN1671407A (zh)	2005-09-21
KR20050048542A (ko)	2005-05-24
CN1671407B (zh)	2010-05-26
US20090269337A1 (en)	2009-10-29
EP1511509B1 (de)	2007-10-10
AU2003243501A1 (en)	2003-12-22
JP2005533775A (ja)	2005-11-10
IL165285A (en)	2010-04-29
DE60329724D1 (de)	2009-11-26
US20040023885A1 (en)	2004-02-05

Publication	Publication Date	Title
DE60329724D1 (de)	2009-11-26	Methoden und Kompositionen um Diabetes zu behandeln
ATE421333T1 (de)	2009-02-15	Behandlung von diabetes.
NO20054407L (no)	2005-12-15	Cannabinoid reseptor ligander og deres anvendelser
NO20013451L (no)	2001-07-12	1-Heterocyklus-substituerte diarylaminer
TW200738270A (en)	2007-10-16	Method of treating depression using a TNFα antibody
NZ593474A (en)	2013-04-26	Compositions and methods for treatment of celiac disease
IL177346A0 (en)	2006-12-10	Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
TR199902033T2 (xx)	2000-02-21	Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
MXPA04001525A (es)	2004-05-31	Analogos de peptido -1 similar al glucagon.
NO20042964L (no)	2004-09-07	Spiroazasykliske forbindelser som monoaminreseptormodulatorer
NO20055516L (no)	2005-11-22	Kannabinoidreceptorligander og anvendelser derav
TW200600087A (en)	2006-01-01	Methods and compositions for treating amyloid-related diseases
IL156828A0 (en)	2004-02-08	Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
MXPA05014166A (es)	2006-03-13	Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
IL195256A0 (en)	2009-08-03	Compositions of r(+)and s(-)pramipexole and methods of using the same
PT1044197E (pt)	2006-07-31	Carboxamidas de piridilalcano, -alceno e -alcino substituidas por piperidinilo como agentes citostaticos e imunossupressores
TW200716088A (en)	2007-05-01	Formulations and methods for treating amyloidosis
TR199901104T2 (xx)	1999-07-21	Farmas�tik bile�ikler.
ATE423990T1 (de)	2009-03-15	Verfahren und zusammensetzungen zur behandlung von uveitis
TW200616639A (en)	2006-06-01	Methods for treating a mammal before, during and after cardiac arrest
TW200507840A (en)	2005-03-01	Method of treating multiple myeloma
PL1626698T3 (pl)	2009-01-30	Opaska formująca
MXPA05011213A (es)	2006-02-17	Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
NO985855L (no)	1999-02-15	Absorberende gjenstander som puster
TR200002072T2 (tr)	2000-12-21	Spiropiperidin türevleri

Legal Events

Date	Code	Title	Description
2010-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties